Research programme: gene-edited iPS cell therapies - Eterna Therapeutics/University of Texas M. D. Anderson Cancer Center
Alternative Names: Gene-edited induced pluripotent stem cell therapies - Eterna Therapeutics/University of Texas M. D. Anderson Cancer CenterLatest Information Update: 09 May 2023
At a glance
- Originator Eterna Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 02 May 2023 Eterna Therapeutics in-licenses allogeneic immuno-oncology platform technology from Exacis Biotherapeutics
- 01 Nov 2022 Eterna Therapeutics enters into R & D agreement with University of Texas M D Anderson Cancer Center for the development of gene-edited iPS cell therapies in Cancer
- 01 Nov 2022 Early research in Cancer in USA (Parenteral)